Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Bentham

Showing results (21-30 of 55) with videos related to

Pageof 6
Sort By:
Alzheimer'S & Dementia (New York, N. Y.)|April 5, 2021
Pharmacological treatment trials of agitation in Alzheimer's disease: A systematic review of ClinicalTrials.gov registered trialsKathy Y Liu, Anya Borissova, Jansher Mahmood, et al.
Frontiers in Computational Neuroscience|December 3, 2016
Classifying Cognitive Profiles Using Machine Learning with Privileged Information in Mild Cognitive ImpairmentHanin H Alahmadi, Yuan Shen, Shereen Fouad, et al.
Current Alzheimer Research|January 5, 2026
Hypertension is the Main Vascular Risk Factor for Cognitive Impairment, Microvascular Pathology and Brain Atrophy in Alzheimer's DiseaseShailendra Mohan Tripathi, Helen Shiells, Jennifer Waymont, et al.
Neurobiology of Aging|November 14, 2006
Role of 5HT 2A and 5HT 2C polymorphisms in behavioural and psychological symptoms of Alzheimer's diseaseAntonia L Pritchard, Judith Harris, Colin W Pritchard, et al.
Nursing Older People|March 1, 2014
Evaluation of dementia training for staff in acute hospital settingsAnalisa Smythe, Catharine Jenkins, Margaret Harries, et al.
Stroke|October 9, 2010
Aspirin in Alzheimer's disease: increased risk of intracerebral hemorrhage: cause for concern?Hanneke Thoonsen, Edo Richard, Peter Bentham, et al.
Journal of Alzheimer'S Disease : JAD|January 1, 2015
Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's diseaseClaude M Wischik, Roger T Staff, Damon J Wischik, et al.
Brain Communications|December 23, 2021
Degeneration of basal and limbic networks is a core feature of behavioural variant frontotemporal dementiaVesna Vuksanović, Roger T Staff, Suzannah Morson, et al.
Neurobiology of Disease|February 15, 2008
Association study of the GAB2 gene with the risk of developing Alzheimer's diseaseJulien Chapuis, Didier Hannequin, Florence Pasquier, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|August 25, 2009
Brief psychosocial therapy for the treatment of agitation in Alzheimer disease (the CALM-AD trial)Clive Ballard, Richard Brown, Jane Fossey, et al.
Pageof 6

Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
Alzheimer'S & Dementia (New York, N. Y.)|April 5, 2021
Pharmacological treatment trials of agitation in Alzheimer's disease: A systematic review of ClinicalTrials.gov registered trialsKathy Y Liu, Anya Borissova, Jansher Mahmood, et al.
Frontiers in Computational Neuroscience|December 3, 2016
Classifying Cognitive Profiles Using Machine Learning with Privileged Information in Mild Cognitive ImpairmentHanin H Alahmadi, Yuan Shen, Shereen Fouad, et al.
Current Alzheimer Research|January 5, 2026
Hypertension is the Main Vascular Risk Factor for Cognitive Impairment, Microvascular Pathology and Brain Atrophy in Alzheimer's DiseaseShailendra Mohan Tripathi, Helen Shiells, Jennifer Waymont, et al.
Neurobiology of Aging|November 14, 2006
Role of 5HT 2A and 5HT 2C polymorphisms in behavioural and psychological symptoms of Alzheimer's diseaseAntonia L Pritchard, Judith Harris, Colin W Pritchard, et al.
Nursing Older People|March 1, 2014
Evaluation of dementia training for staff in acute hospital settingsAnalisa Smythe, Catharine Jenkins, Margaret Harries, et al.
Stroke|October 9, 2010
Aspirin in Alzheimer's disease: increased risk of intracerebral hemorrhage: cause for concern?Hanneke Thoonsen, Edo Richard, Peter Bentham, et al.
Journal of Alzheimer'S Disease : JAD|January 1, 2015
Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's diseaseClaude M Wischik, Roger T Staff, Damon J Wischik, et al.
Brain Communications|December 23, 2021
Degeneration of basal and limbic networks is a core feature of behavioural variant frontotemporal dementiaVesna Vuksanović, Roger T Staff, Suzannah Morson, et al.
Neurobiology of Disease|February 15, 2008
Association study of the GAB2 gene with the risk of developing Alzheimer's diseaseJulien Chapuis, Didier Hannequin, Florence Pasquier, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|August 25, 2009
Brief psychosocial therapy for the treatment of agitation in Alzheimer disease (the CALM-AD trial)Clive Ballard, Richard Brown, Jane Fossey, et al.
Pageof 6